Top

Published in:

01-06-2014 | Review

Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors—Fighting Diabetes from a New Perspective

Authors: Theodoros P. Angelopoulos, John Doupis

Published in: Advances in Therapy | Issue 6/2014

Abstract

Sodium-Glucose linked transporter 2 (SGLT2) inhibitors are a new family of antidiabetic pharmaceutical agents whose action is based on the inhibition of the glucose reabsorption pathway, resulting in glucosuria and a consequent reduction of the blood glucose levels, in patients with type 2 diabetes mellitus. Apart from lowering both fasting and postprandial blood glucose levels, without causing hypoglycemia, SGLT2 inhibitors have also shown a reduction in body weight and the systolic blood pressure. This review paper explores the renal involvement in glucose homeostasis providing also the latest safety and efficacy data for the European Medicines Agency and U.S. Food and Drug Administration approved SGLT2 inhibitors, looking, finally, into the future of this novel antidiabetic category of pharmaceutical agents.

Available only for authorised users

Ginter E, Simko V. Type 2 diabetes mellitus, pandemic in 21st century. Adv Exp Med Biol. 2012;771:42–50.PubMed

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.PubMedCrossRef

Fu J, Prasad HC. Changing epidemiology of metabolic syndrome and type 2 diabetes in Chinese youth. Curr Diabetes Rep. 2014;14:447.CrossRef

Sherwin R, Jastreboff AM. Year in diabetes 2012: the diabetes tsunami. J Clin Endocrinol Metab. 2012;97:4293–301.PubMedCentralPubMedCrossRef

Tentolouris N, Katsilambros N. Textbook of Diabetes. In: Pickup JC, Williams G, editors. Type 2 diabetes: an overview. 3rd ed. Oxford: Blackwell Publishing; 2003. p. 4.1–4.19.

Triplitt CL. Understanding the kidneys’ role in blood glucose regulation. Am J Manag Care. 2012;18(1 Suppl):S11–6.PubMed

Schoolwerth A, Smith B, Culpepper R. Renal gluconeogenesis: a review. Miner Electrolyte Metab. 1988;14:347–61.PubMed

Hutton JC, O’Brien RM. Glucose-6-phosphatase catalytic subunit gene family. J Biol Chem. 2009;284:29241–5.PubMedCentralPubMedCrossRef

Wright E, Hirayama B, Loo D. Active sugar transport in health and disease. J Int Med. 2007;261:32–43.CrossRef

10.

Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009;53:875–83.PubMedCrossRef

11.

Mather A, Pollock C. Glucose handling by the kidney. Kidney Int Suppl. 2011;120:S1–6. doi:10.1038/ki.2010.509.

12.

Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. 2001;24:382–91.PubMedCrossRef

13.

Cersosimo E, Garlick P, Ferretti J. Insulin regulation of renal glucose metabolism in humans. Am J Physiol. 1999;276:E78–84.PubMed

14.

Stumvoll M, Meyer C, Kreider M, Perriello G, Gerich J. Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsorptive humans. Metabolism. 1998;47:1227–32.PubMedCrossRef

15.

Meyer C, Stumvoll M, Nadkarni V, Dostou J, Mitrakou A, Gerich J. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest. 1998;102:619–24.PubMedCentralPubMedCrossRef

16.

Kitabchi AE, Umpierrez GE, Fisher JN, Murphy MB, Stentz FB. Thirty years of personal experience in hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. J Clin Endocrinol Metab. 2008;93:1541–52.PubMedCentralPubMedCrossRef

17.

Meyer C, Dostou JM, Welle SL, Gerich JE. Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis. Am J Physiol Endocrinol Metab. 2002;282:E419–27.PubMed

18.

Gerich JE. Physiology of glucose homeostasis. Diabetes Obes Metab. 2000;2:345–50.PubMedCrossRef

19.

Guyton AC, Hall JE. Chapter 27: Urine formation by the kidneys: II tubular processing of the glomerular filtrate. In: Guyton AC, Hall JE, editors. Textbook of medical physiology. 11th ed. Philadelphia: Elsevier Saunders; 2006. p. 327–47.

20.

Zelikovic I. Aminoaciduria and glycosuria. In: Avner ED, Harmon WE, Niaudet P, editors. Pediatric nephrology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 701–28.

21.

Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol. 2003;14:2873–82.PubMedCrossRef

22.

Turk E, Zabel B, Mundlos S, Dyer J, Wright EM. Glucose/galactose malabsorption caused by a defect in the Na⁺/glucose cotransporter. Nature. 1991;350:354–6.PubMedCrossRef

23.

Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21:31–8.PubMedCrossRef

24.

Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79:1510–5.PubMedCentralPubMedCrossRef

25.

Dimitrakoudis D, Vranic M, Klip A. Effects of hyperglycemia on glucose transporters of the muscle: use of the renal glucose reabsorption inhibitor phlorizin to control glycemia. J Am Soc Nephrol. 1992;3:1078–91.PubMed

26.

Pierson R. EU okays Bristol-Astra diabetes drug after US rejection. Reuters. (2012).Available from: http://www.reuters.com/article/2012/11/14/us-bristolmyers-astrazeneca-diabetes-idUSBRE8AD1JR20121114 (accessed April 10, 2014).

27.

Clarke T. U.S. FDA approves Johnson & Johnson diabetes drug, canagliflozin. Reuters; 2013. Available from: http://www.reuters.com/article/2013/03/29/johnsonjohnson-diabetes-idUSL3N0CL1FV20130329 (accessed April 10, 2014).

28.

European Commission: http://ec.europa.eu/health/documents/community-register/html/newproc.htm#h (accessed April 10, 2014).

29.

Han S, Hagan DL, Taylor JR. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57:1723–9.PubMedCrossRef

30.

Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85:513–9.PubMedCrossRef

31.

Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217–24.PubMedCentralPubMedCrossRef

32.

Boldys A, Okopien B. Inhibitors of type 2 sodium glucose co-transporters—a new strategy for diabetes treatment: review. Pharmacol Rep. 2009;61:778–84.PubMedCrossRef

33.

Wilding JP, Norwood P, T’joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32:1656–62.PubMedCentralPubMedCrossRef

34.

List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-Glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650–7.PubMedCentralPubMedCrossRef

35.

Komala MG, Panchapakesan U, Pollock C, Mather A. Sodium glucose cotransporter 2 and the diabetic kidney. Curr Opin Nephrol Hypertens. 2013;22:113–9.PubMedCrossRef

36.

Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223–33.PubMedCrossRef

37.

Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–31.PubMedCrossRef

38.

Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13:928–38.PubMedCrossRef

39.

Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35:1473–8.PubMedCentralPubMedCrossRef

40.

Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015–22.PubMedCentralPubMedCrossRef

41.

Jabbour SA, Whaley JM, Tirmenstein M, et al. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin. Postgrad Med. 2012;124:62–73.PubMedCrossRef

42.

Gerich JE, Bastien A. Development of the Sodium-Glucose co-transporter 2 inhibitor dapaglifloz in for the treatment of patients with type 2 diabetes mellitus. Expert Rev Clin Pharmacol. 2011;4:669–83.PubMedCrossRef

43.

Shah NK, Deeb WE, Choksi R, Epstein BJ. Dapagliflozin: a novel Sodium-Glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy. 2012;32:80–94.PubMedCrossRef

44.

Bhartia M, Tahrani AA, Barnett AH. SGLT-2 inhibitors in development for type 2 diabetes treatment. Rev Diabetes Stud. 2011;8:348–54.CrossRef

45.

FDA Advisory Committee Meeting. FDA briefing document. NDA 202293. (Dapagliflozin tablets 5 mg and 10 mg. Sponsor: Bristol Myers Squibb); 2011. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM262994.pdf (accessed April 10, 2014).

46.

Abdul-Ghani MA, Norton L, de Fronzo RA. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr. Diabetes Rep. 2012;1:230–8.CrossRef

47.

Kasichayanula S, Liu X, Shyu WC, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel Sodium-Glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011;13:47–54.PubMedCrossRef

48.

Kasichayanula S, Liu X, Zhang W, Pfister M, LaCreta FP, Boulton DW. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clin Ther. 2011;33:1798–808.PubMedCrossRef

49.

Ljunggren Ö, Bolinder J, Johansson L. Dapagliflozin has no effect on markers of bone formation and resorption of bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012;14:990–9.PubMedCrossRef

50.

Scheen AJ. Drug–drug interactions with Sodium-Glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus. Clin Pharmacokinet. 2014;53:295–304.PubMedCrossRef

51.

Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–71.PubMedCentralPubMedCrossRef

52.

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58). Available from: http://www.clinicaltrials.gov/show/NCT01730534 (accessed April 10, 2014).

53.

Vouyiouklis M. Canagliflozin: improving diabetes by making urine sweet. Cleve Clin J Med. 2013;80:683–7.PubMedCrossRef

54.

Doggrell SA, McIntyre K. Canagliflozin—something new for type 2 diabetes, but is it safe and efficacious? Expert Opin Pharmacother. 2014;15(3):437–41.PubMedCrossRef

55.

Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372–82.PubMedCentralPubMedCrossRef

56.

Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14:539–45.PubMedCrossRef

57.

Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74:807–24.PubMedCrossRef

58.

Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a Sodium-Glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35:1232–8.PubMedCentralPubMedCrossRef

59.

Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012;28:1173–8.PubMedCrossRef

60.

Stenlöf K, Cefalu WT, Kim KA. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014;30:163–75.PubMedCrossRef

61.

FDA Advisory Committee Meeting. FDA briefing document. NDA 204042. (Invokana (canagliflozin) Tablets, Applicant: Janssen Pharmaceuticals, Inc. (2013). Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf (accessed April 10, 2014).

62.

Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463–73.PubMedCentralPubMedCrossRef

63.

Weir MR, Kline I, Xie J, Edwards R, Usiskin K. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin. 2014;22:1–10.CrossRef

64.

Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2014;382:941–50.CrossRef

65.

Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)–a randomized placebo-controlled trial. Am Heart J. 2013;166:217–23.PubMedCrossRef

66.

Janssen Research & Development, LLC. First Results from Phase 3 CANVAS Trial Show Canagliflozin as Add-on Therapy to Insulin Lowered Blood Sugar Levels in Patients with Type 2 Diabetes at an Elevated Risk for Cardiovascular Disease. (2012). Available from: http://www.jnj.com/news/all/phase-3-canvas-trial-show-canagliflozin-as-add-on-therapy-to-insulin-lowered-blood-sugar-levels-in-patients-with-type-2-diabetes-at-an-elevated-risk-for-cardiovascular-disease (accessed April 10, 2014).

67.

Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013;27(6):453–67.

68.

Ridderstråle M, Svaerd R, Zeller C, Kim G, Woerle HJ, Broedl UC. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovasc Diabetol. 2013;12:129.PubMedCentralPubMedCrossRef

69.

Tahara A, Kurosaki E, Yokono M, et al. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin–nicotinamide-induced mildly diabetic mice. Pharmacol Sci. 2012;120:36–44.CrossRef

70.

Suzuki M, Honda K, Fukazawa M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012;341:692–701.PubMedCrossRef

71.

Hussey EK, Kapur A, O’Connor-Semmes R, et al. Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol. 2013;30:14–25.

72.

Zanardi TA, Han SC, Jeong EJ, Rime S, Yu RZ, Chakravarty K, Henry SP. Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2. J Pharmacol Exp Ther. 2012;343:489–96.PubMedCrossRef

Title: Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors—Fighting Diabetes from a New Perspective
Authors: Theodoros P. Angelopoulos
John Doupis
Publication date: 01-06-2014
Publisher: Springer Healthcare
Published in: Advances in Therapy / Issue 6/2014
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI: https://doi.org/10.1007/s12325-014-0127-7

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2014

Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial

Safety and Tolerability of Tapentadol Extended Release in Moderate to Severe Chronic Osteoarthritis or Low Back Pain Management: Pooled Analysis of Randomized Controlled Trials

24-Hour Efficacy of Travoprost/Timolol BAK-Free Versus Latanoprost/Timolol Fixed Combinations in Patients Insufficiently Controlled with Latanoprost

The Clinical Impact of Different Coagulometers on Patient Outcomes

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage